Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986205 and Nivolumab in Advanced Malignant Tumors
NCT03192943Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2017
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 1, open-label trial of linrodostat in cancer, sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events at 15 months and Incidence of Serious Adverse Events at 15 months. Started Jun 2017; status: completed.
02
Drugs
linrodostat
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03192943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192943.